SLC13A5-IN-1

• UNSPSC Description:

  SLC13A5-IN-1 is a selective sodium-citrate co-transporter (SLC13A5) inhibitor. SLC13A5-IN-1 completely blocks?the uptake of?14C-citrate with an IC50 value of 0.022 μM in HepG2 cells. SLC13A5-IN-1 has the potential for the treatment of metabolic and/or cardiovascular diseases. SLC13A5-IN-1 is extracted from patent WO2018104220A1, Compound I-5[1].

• Target Antigen:

  Sodium Channel

• Type:

  Reference compound

• Related Pathways:

  Membrane Transporter/Ion Channel

• Field of Research:

  Metabolic Disease; Cardiovascular Disease

• Assay Protocol:

  https://www.medchemexpress.com/slc13a5-in-1.html

• Purity:

  99.79

• Solubility:

  DMSO : 12.5 mg/mL (ultrasonic;warming;heat to 60°C)

• Smiles:

  O=C(C1CCN(S(=O)(C2=CC(Cl)=CC(Cl)=C2)=O)CC1)NCC3=CC=C(Cl)C=C3

• Molecular Weight:

  461.79

• References & Citations:

  [1]Joerg Kley, et al. Sulfonamides as inhibitors of the uptake of extracellular citrate. Patent WO2018104220A1

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Clinical Information:

  No Development Reported

• CAS Number:

  2227548-95-8